rfHSA
rfHSA
Treatment of cancers with refolding human serum albumin
用複性人血清白蛋白治療癌症
Targeted indication
Anti-cancers, Ovarian, lung cancer etc.
Status
Pre-clinical studies
Key features
- Easy to manufacture
- Cost efficient
- High stability of rfHSA
Market
The treatment for advanced ovarian and lung cancer is presently an unmet clinical need.
Through murine xenograft models, the research team has confirmed that rfHSA inhibits the growth and metastasis of ovarian cancer tumors and prolongs the life span of human tumor bearing mice, indicating the curative potential of rfHSA for ovarian and lung cancer.
Moreover, rfHSA exhibits synergistic effect with cisplatin or doxorubicin to inhibit cancer with higher efficacy as well as lower drug resistance and toxicity
MODE OF ACTION
The research team has developed a simple chromatography method to refold globular form human serum albumin (gHSA) to oval form albumin (rfHSA) that inhibits the growth and metastasis of a variety of cancer cell lines.
EXPERIMENTAL RESULTS
rfHSA inhibits the growth and migration/invasion of a variety of cancer cell lines
rfHSA inhibits the growth and metastasis of ovarian and lung cancer and prolongs the life span of human tumor xenograft mice
In terms of toxicity and immunogenicity in rodent model, rfHSA is about the same as gHSA
Exhibition of synergistic effect with cisplatin or doxorubicin to inhibit cancer with higher efficacy as well as lower drug resistance and toxicity
Scale up of production process for commercialization
Development of a mass spectrometry method to distinguish between rfHSA and gHSA. This method can be applied for the quality control (QC)/quality assurance (QA) as well as Chemistry, Manufacturing and Controls (CMC)
Generation of specific anti-rfHSA monoclonal antibodies to set up of an ELISA method for pharmacokinetics and toxicology examination of rfHSA in monkey and human blood.
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
1. Cancer Res. 73:439-449 (2013).
2. Oncogene 32:777-787 (2013).
3. Autophagy (in press)
BUSINESS OPPORTUNITY
License and/or Collaboration and Sponsored Research
CONTACT
service@biip-dcc.org